These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 29865055)

  • 21. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model.
    Castillo-Carranza DL; Guerrero-Muñoz MJ; Sengupta U; Hernandez C; Barrett AD; Dineley K; Kayed R
    J Neurosci; 2015 Mar; 35(12):4857-68. PubMed ID: 25810517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease.
    Jazvinšćak Jembrek M; Slade N; Hof PR; Šimić G
    Prog Neurobiol; 2018 Sep; 168():104-127. PubMed ID: 29733887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synaptic Impairment in Alzheimer's Disease: A Dysregulated Symphony.
    Forner S; Baglietto-Vargas D; Martini AC; Trujillo-Estrada L; LaFerla FM
    Trends Neurosci; 2017 Jun; 40(6):347-357. PubMed ID: 28494972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Co-oligomers of Aβ42 and Human Islet Amyloid Polypeptide Exacerbate Neurotoxicity and Alzheimer-like Pathology at Cellular Level.
    Deng J; Liu B; Tao Q; Luo Y; Zhu Y; Huang X; Yue F
    Neuroscience; 2024 May; 547():37-55. PubMed ID: 38604526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain amyloid-β oligomers in ageing and Alzheimer's disease.
    Lesné SE; Sherman MA; Grant M; Kuskowski M; Schneider JA; Bennett DA; Ashe KH
    Brain; 2013 May; 136(Pt 5):1383-98. PubMed ID: 23576130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and tau pathology underlying Alzheimer's disease.
    Barbero-Camps E; Fernández A; Martínez L; Fernández-Checa JC; Colell A
    Hum Mol Genet; 2013 Sep; 22(17):3460-76. PubMed ID: 23648430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer's disease as oligomeropathy.
    Ono K
    Neurochem Int; 2018 Oct; 119():57-70. PubMed ID: 28821400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The zinc dyshomeostasis hypothesis of Alzheimer's disease.
    Craddock TJ; Tuszynski JA; Chopra D; Casey N; Goldstein LE; Hameroff SR; Tanzi RE
    PLoS One; 2012; 7(3):e33552. PubMed ID: 22457776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Abeta and tau in Alzheimer's disease, an early interim report.
    Golde TE; Petrucelli L; Lewis J
    Exp Neurol; 2010 Jun; 223(2):252-66. PubMed ID: 19716367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
    Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
    J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spreading of Pathology in Alzheimer's Disease.
    Lv ZY; Tan CC; Yu JT; Tan L
    Neurotox Res; 2017 Nov; 32(4):707-722. PubMed ID: 28623460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Untangling amyloid-β, tau, and metals in Alzheimer's disease.
    Savelieff MG; Lee S; Liu Y; Lim MH
    ACS Chem Biol; 2013 May; 8(5):856-65. PubMed ID: 23506614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease.
    Morris GP; Clark IA; Vissel B
    Acta Neuropathol Commun; 2014 Sep; 2():135. PubMed ID: 25231068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
    Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
    Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synaptic Dysfunction in Alzheimer's Disease: Aβ, Tau, and Epigenetic Alterations.
    Li K; Wei Q; Liu FF; Hu F; Xie AJ; Zhu LQ; Liu D
    Mol Neurobiol; 2018 Apr; 55(4):3021-3032. PubMed ID: 28456942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Familial Alzheimer's disease mutations at position 22 of the amyloid β-peptide sequence differentially affect synaptic loss, tau phosphorylation and neuronal cell death in an ex vivo system.
    Tackenberg C; Kulic L; Nitsch RM
    PLoS One; 2020; 15(9):e0239584. PubMed ID: 32966331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer's Disease.
    Caccamo A; Branca C; Talboom JS; Shaw DM; Turner D; Ma L; Messina A; Huang Z; Wu J; Oddo S
    J Neurosci; 2015 Oct; 35(41):14042-56. PubMed ID: 26468204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer's disease model.
    Goñi F; Martá-Ariza M; Herline K; Peyser D; Boutajangout A; Mehta P; Drummond E; Prelli F; Wisniewski T
    Alzheimers Res Ther; 2018 Jan; 10(1):10. PubMed ID: 29378642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alzheimer's associated amyloid and tau deposition co-localizes with a homeostatic myelin repair pathway in two mouse models of post-stroke mixed dementia.
    Nguyen TV; Hayes M; Zbesko JC; Frye JB; Congrove NR; Belichenko NP; McKay BS; Longo FM; Doyle KP
    Acta Neuropathol Commun; 2018 Sep; 6(1):100. PubMed ID: 30249297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.